Organ-site efficacy
Evaluate treatment response in anatomically matched tumor settings using project-specific intervention schedules.
ONCOLOGY MODEL
Orthotopic Tumor Models
Documented orthotopic platforms include human xenograft and syngeneic tumor models across hematologic, lung, pancreatic, liver, brain, colorectal, and breast cancer settings.
Tumor line, implantation site, imaging strategy, host background, treatment schedule, and tissue outputs are confirmed per program.
MODEL OVERVIEW
Organ-site tumor modeling for oncology programs that need anatomical context.
Orthotopic tumor studies place the model in a disease-relevant anatomical site and can incorporate luciferase-enabled lines, imaging, tissue collection, and project-specific pharmacology endpoints where appropriate.
Therapeutic areaOncology
SpeciesMouse
Model formatOrthotopic xenograft, syngeneic
Typical useEfficacy, Imaging, Tissue analysis
TYPICAL APPLICATIONS
What this model can support.
Imaging-enabled studies
Luciferase-enabled tumor lines can support longitudinal imaging where documented and appropriate to the model.
Tissue-level pharmacology
Collect primary tumor and other protocol-defined tissues for pathology, biomarkers, or downstream molecular analysis.
PK/PD integration
Combine systemic or tissue exposure with pharmacodynamic and efficacy readouts when required.
COMMON READOUTS
Readouts selected around the study question.
Endpoints are finalized with the selected model, species or strain, treatment design, and partner laboratory before study placement.
Tumor burden
Protocol-defined measurements of tumor burden or treatment response.
Imaging
Longitudinal in vivo imaging for compatible luciferase-enabled models.
Tissue analysis
Histology, IHC, molecular, or other downstream analysis on collected tissues.
Exposure
Plasma, tumor, or selected tissue exposure when incorporated into the study.
Exact tumor line, host strain, implantation technique, imaging workflow, endpoints, and timeline are confirmed during technical review.
STUDY DESIGN
Key factors aligned before execution.
- Tumor type and cell line
- Orthotopic implantation site
- Host background
- Imaging compatibility
- Treatment route and schedule
- Required tissue and PK/PD outputs
Discuss Your Program
Share the compound, mechanism, development question, preferred model, and intended endpoints. We can review fit, feasibility, and the appropriate partner-laboratory route for a Orthotopic study.Required fields are marked with an asterisk(*).